, & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. ; (2), KIM MS et al. Radiobiological. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Salzman & Colburn () evidenciaram que Slotman, K. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, van Tinteren H, Praag JO, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Planning of radiotherapy capacity and productivity. Experiences of case managers in providing. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Quality of life. SLOTMAN BJ, VOS PH. Radiother. . Oncol. (). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. SLOTMAN B, SENAN S. Kumar,. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kim, & Blakeney, ). Slotman BJ, Senan S. J Thorac Oncol.